While the VeriStrat proteomic classifier has mainly been used in the setting of NSCLC, a recent study showed prognostic value of VeriStrat for PFS and OS in afatinib (EGFR TKI)-treated recurrent/metastatic HNSCC patients, and OS in methotrexate-treated HNSCC patients. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.